Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance

被引:78
|
作者
Videira, Mafalda [1 ,2 ]
Reis, Rita Leones [1 ]
Brito, Maria Alexandra [1 ,3 ]
机构
[1] Univ Lisbon, Fac Farm, Res Inst Med iMed ULisboa, P-1649003 Lisbon, Portugal
[2] Univ Lisbon, Fac Farm, Dept Galen Pharm & Pharmaceut Technol, P-1649003 Lisbon, Portugal
[3] Univ Lisbon, Fac Farm, Dept Biochem & Human Biol, P-1649003 Lisbon, Portugal
来源
关键词
Cancer biology; Chemoresistance; Efflux transporters; Epithelial-mesenchymal transition; Multidrug resistance proteins; Tumor microenvironment; TO-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; P-GLYCOPROTEIN INHIBITOR; IN-VIVO REVERSAL; FACTOR-KAPPA-B; DRUG-RESISTANCE; STEM-CELLS; PROTEIN BCRP/ABCG2; PHOSPHATIDYLINOSITOL; 3-KINASE;
D O I
10.1016/j.bbcan.2014.07.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer complexity constantly challenges the way that clinicians manage breast cancer therapy. Tumor heterogeneity and intratumoral stroma characteristics allow cells with different phenotypes and deregulated apoptotic, proliferative and migration abilities to co-exist contributing to a disappointing therapeutic response. While new approaches are being associated with conventional chemotherapy, such as hormonal therapy or target monoclonal antibodies, recurrence and metastasization are still observed. Membrane transporters are the cell's first line of contact with anticancer drugs having a major role in multidrug resistance events. This structural-based activity enables the cell to be drug-resistant by decreasing drug intracellular concentration through an efflux-transport mechanism, mainly associated with overexpression of ATP-binding cassette (ABC) proteins. This review focuses on some of the important structural and biological properties of the malignant cell and tumor microenvironment, addressing the role of the membrane ABC transporters in therapeutic outcomes, and highlighting related molecular pathways that may represent meaningful target therapies. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:312 / 325
页数:14
相关论文
共 50 条
  • [21] Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer
    Murren, JR
    Durivage, HJ
    Buzaid, AC
    Reiss, M
    Flynn, SD
    Carter, D
    Hait, WN
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (01) : 65 - 70
  • [22] DECONSTRUCTING HEMATOPOIETIC STEM CELL BIOLOGY
    Passegue, Emmannuelle
    EXPERIMENTAL HEMATOLOGY, 2014, 42 (08) : S11 - S11
  • [23] Understanding the molecular mechanisms of enzalutamide resistance in breast cancer cell lines
    Arroyo-Garrapucho, Nuria
    Garcia-Rodriguez, Sara
    Gestoso-Uzal, Nerea
    Herrero, Ana-Belen
    Gonzalez-Sarmiento, Rogelio
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 550 - 550
  • [24] Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo
    Chen, Si-Ying
    Hu, Sa-Sa
    Dong, Qian
    Cai, Jiang-Xia
    Zhang, Wei-Peng
    Sun, Jin-Yao
    Wang, Tao-Tao
    Xie, Jiao
    He, Hai-Rong
    Xing, Jian-Feng
    Lu, Jun
    Dong, Ya-Lin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (10) : 6135 - 6140
  • [25] Mechanisms of Trastuzumab Resistance in Breast Cancer
    Tolaney, Sara M.
    Krop, Ian E.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (03) : 348 - 355
  • [26] Mechanisms of Endocrine Resistance in Breast Cancer
    Osborne, C. Kent
    Schiff, Rachel
    ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 : 233 - 247
  • [27] Mechanisms of endocrine resistance in breast cancer
    Per E Lnning
    中华乳腺病杂志(电子版), 2012, 6 (06) : 597 - 608
  • [28] Multifunctional Nanoparticles Improve Therapeutic Effect for Breast Cancer by Simultaneously Antagonizing Multiple Mechanisms of Multidrug Resistance
    Yin, Qi
    Shen, Jianan
    Zhang, Zhiwen
    Yu, Haijun
    Chen, Lingli
    Gu, Wangwen
    Li, Yaping
    BIOMACROMOLECULES, 2013, 14 (07) : 2242 - 2252
  • [29] Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer
    Taruma Fujii
    S. Q. Fu
    L. H. Yin
    T. Nanakorn
    Felix Garcia Sanchez
    Matt Cooperberg
    David Guo
    Twang Lin D.
    Giuseppe Pizzorno
    Albert Deisseroth
    Breast Cancer, 1997, 4 (4) : 210 - 212
  • [30] Deconstructing breast cancer reconstruction
    Allison, Cecelia
    Fear, David
    CANCER RESEARCH, 2020, 80 (04)